The analgesics market is projected to reach $132.6 billion by 2030 at a 3.4% CAGR, driven by personalized pain management, opioid alternatives, and digital healthcare expansion.
Read More
The anakinra market is projected to reach $9.61 billion by 2030 at an 11.9% CAGR, driven by biologic therapies, rare disease treatment, and home-based care expansion.
Read More
The aminoglycosides market is projected to reach $2.56 billion by 2030 at a 6.0% CAGR, driven by targeted therapies, advanced drug delivery, and veterinary & ophthalmic applications.
Read More
The Alzheimer’s drugs market is projected to reach $15.4 billion by 2030 at an 8.8% CAGR, driven by precision medicine, AI integration, neuroprotective therapies, and early diagnosis.
Read More
The Alzheimer’s disease treatment market is projected to reach $9.51 billion by 2030 at a 6.6% CAGR, driven by immunotherapies, combination therapies, and early diagnosis initiatives.
Read More
The alpha methyldopa market is projected to reach $17.3 billion by 2030 at an 8.9% CAGR, driven by maternal healthcare use, oral formulations, and global hypertension programs.
Read More
The alpha mannosidosis market is projected to reach $39.41 billion by 2030 at a 17.0% CAGR, driven by gene therapies, enzyme replacement, and rare disease initiatives.
Read More
The alpha glucosidase inhibitors market is projected to reach $7.05 billion by 2030 at an 8.0% CAGR, driven by combination therapies, digital health, and personalized diabetes care.
Read More
The alopecia treatment market is projected to reach $13.75 billion by 2030 at a 6.3% CAGR, driven by biologics, JAK inhibitors, hair transplants, and personalized dermatology.
Read More
The allogeneic T cell therapies market is projected to reach $1.98 billion by 2030 at a 9.4% CAGR, driven by off-the-shelf cell therapies, oncology pipelines, and scalable manufacturing.
Read More